© 2021 MJH Life Sciences and Psychiatric Times. All rights reserved.
© 2021 MJH Life Sciences™ and Psychiatric Times. All rights reserved.
July 20, 2021
An extended release, ultra-long acting antipsychotic takes another step forward in the approval process.
July 19, 2021
After the largest increase in overdose deaths in 50 years, the American Psychiatric Association sends out the call for improved substance use care.
July 16, 2021
If approved, SLS-002 would be only the second approved product for ASIB.
New research may help better understand psychosis etiology as well as provide potential biomarkers for psychosis.
July 15, 2021
Novel digital therapy modia will be evaluated in combination with sublingual buprenorphine/naloxone background therapy to see whether it is superior in reducing opioid use.
July 09, 2021
To combat drug overdoses, the Rhode Island governor signed a bill allowing people to consume pre-obtained drugs under safe, professional supervision of trained staff.
July 08, 2021
Following criticism for its wide-labeled June approval, the FDA has decided to narrow the patient recommendation for aducanumab.
June 25, 2021
Donanemab for the treatment of Alzheimer disease has received Breakthrough Therapy designation from the FDA.
For the first time since 2015, Scottish Parliament is considering legislation on medical aid in dying.
June 24, 2021
The 2021 American Psychiatric Association Virtual Annual Meeting brought together leaders in psychiatry to discuss hot topics including diversity, COVID-19, mood disorders, and more.